Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 82854-37-3
2. Dsstox_cid_13469
3. Chebi:4745
4. I04o1dt48t
5. [(2r,3r,4r,5r,6r)-6-[2-(3,4-dihydroxyphenyl)ethoxy]-5-hydroxy-2-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]-4-[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl] (e)-3-(3,4-dihydroxyphenyl)prop-2-enoate
6. Ac1nqz1q
7. Unii-i04o1dt48t
8. Echinacoside,(s)
9. Mfcd00075695
10. Surecn525502
11. Dsstox_rid_79077
12. Dsstox_gsid_33469
13. Echinacoside [usp-rs]
14. Echinacoside, 98% (hplc)
15. Schembl525502
16. Chembl510539
17. Megxp0_001773
18. Dtxsid0033469
19. Echinacoside, Analytical Standard
20. Hms3885k04
21. Hy-n0020
22. Tox21_200945
23. S3783
24. Zinc85504689
25. Akos015897141
26. Ccg-270479
27. Cs-3400
28. Db15488
29. Ncgc00091915-01
30. Ncgc00091915-02
31. Ncgc00258498-01
32. Ac-34699
33. As-56376
34. Glucopyranoside, 2-(3,4-dihydroxyphenyl)ethyl O-6-deoxy-alpha-l-mannopyranosyl-(1-3)-o-(beta-d-glucopyranosyl-(1-6))-, 4-(3-(3,4-dihydroxyphenyl)-2-propenoate), Beta-d-
35. Cas-82854-37-3
36. A12039
37. 854e373
38. Q475631
39. Echinacoside, Primary Pharmaceutical Reference Standard
40. Echinacoside, United States Pharmacopeia (usp) Reference Standard
41. (2r,3r,4r,5r,6r)-6-(3,4-dihydroxyphenethoxy)-5-hydroxy-2-((((2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yl)oxy)methyl)-4-(((2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyltetrahydro-2h-pyran-2-yl)oxy)tetrahydro-2h-pyran-3-yl 3-(3,4-dihydroxyphenyl)acrylate
42. .beta.-d-glucopyranoside, 2-(3,4-dihydroxyphenyl)ethyl O-6-deoxy-.alpha.-l-mannopyranosyl-(1->3)-o-(.beta.-d-glucopyranosyl-(1->6))-, 4-(3-(3,4-dihydroxyphenyl)-2-propenoate)
43. [(2r,3r,4r,5r,6r)-6-[2-(3,4-dihydroxyphenyl)ethoxy]-5-hydroxy-2-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxymethyl]-4-[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyl-tetrahydropyran-2-yl]oxy-tetrahydropyran-3-yl] (e)-3-(3,4-dihydroxyphenyl)prop-2-enoate
44. 2-(3,4-dihydroxyphenyl)ethyl 6-deoxy-alpha-l-mannopyranosyl-(1-3)-[beta-d-glucopyranosyl-(1-6)]-4-o-[(2e)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]-beta-d-glucopyranoside
45. 3,4-dihydroxyphenethyl 3-o-(alpha-l-rhamnopyranosyl)-4-o-(3,4-dihydroxycinnamoyl)-6-o-(beta-d-glucopyranosyl)-beta-d-glucopyranoside
46. 737806-07-4
47. Echinacoside (ang, Pal) (constituent Of Echinacea Angustifolia Root, Echinacea Pallida Root, Echinacea Purpurea Root And Echinacea Purpurea Aerial Parts) [dsc]
48. Ncgc00091915-03![(2r,3r,4r,5r,6r)-6-[2-(3,4-dihydroxyphenyl)ethoxy]-5-hydroxy-2-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]-4-[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl] (e)-3-(3,4-dihydroxyphenyl)prop-2-enoate
Molecular Weight | 786.7 g/mol |
---|---|
Molecular Formula | C35H46O20 |
XLogP3 | -2.1 |
Hydrogen Bond Donor Count | 12 |
Hydrogen Bond Acceptor Count | 20 |
Rotatable Bond Count | 14 |
Exact Mass | 786.25824385 g/mol |
Monoisotopic Mass | 786.25824385 g/mol |
Topological Polar Surface Area | 324 Ų |
Heavy Atom Count | 55 |
Formal Charge | 0 |
Complexity | 1230 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 15 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 1 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Absorption
Animal studies suggest an oral bioavailability of 0.83%.
The metabolism of echinacoside has been investigated in rats and is thought to involve catechol O-methyltransferase as well as unspecified UDP-gluc- uronosyltransferases and sulfotransferases. A study of echinacoside's metabolism by human intestinal flora identified 13 metabolites which are produced independantly of human metabolism.
The neuroprotective effects are thought to be mediated via effects on mitogen-activated protein kinase, nuclear factor kappa-B, caspases 3 and 8, as well as CHOP pathways.
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?